Long-term use of proton pump inhibitors was associated with rapid progression to end stage kidney disease in a Korean nationwide study.

Proton pump inhibitors (PPIs) are among the most widely used drugs worldwide. However, their influence on the progression of end-stage kidney disease (ESKD) in established chronic kidney disease (CKD) cases is unclear. Using the Korean Health Insurance Review and Assessment database encoded by the Observational Medical Outcomes Partnership-Common Data Model (OMOP-CDM), patients with stage 3 or 4 CKD initiating PPIs or histamine-2 receptor antagonists (H2RAs) for over 90 days were enrolled from 2012 through 2021.

Uncertainty Quantification in Automated Detection of Vertebral Metastasis Using Ensemble Monte Carlo Dropout.

The accurate and early detection of vertebral metastases is crucial for improving patient outcomes. Although deep-learning models have shown potential in this area, their lack of prediction reliability and robustness limits their clinical utility. To address these challenges, we propose a novel technique called Ensemble Monte Carlo Dropout (EMCD) for uncertainty quantification (UQ), which combines the Monte Carlo dropout and deep ensembles.

Painting Cell-Cell Interactions by Horseradish Peroxidase and Endogenously Generated Hydrogen Peroxide.

Cell-cell interactions are fundamental in biology for maintaining physiological conditions with direct contact being the most straightforward mode of interaction. Recent advancements have led to the development of various chemical tools for detecting or identifying these interactions. However, the use of exogenous cues, such as toxic reagents, bulky probes, and light irradiation, can disrupt normal cell physiology.

Lecanemab: Appropriate Use Recommendations by Korean Dementia Association.

Lecanemab (product name Leqembi®) is an anti-amyloid monoclonal antibody treatment approved for use in Korea for patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease. The Korean Dementia Association has created recommendations for the appropriate use of lecanemab to assist clinicians. These recommendations include selecting patients for administration, necessary pre-administration tests and preparations, administration methods, monitoring for amyloid related imaging abnormalities (ARIA), and communication with patients and caregivers.